Platelet-endothelial interactions in atherothrombotic disease: Therapeutic implications

Clinical Cardiology

Volumn 22, Issue 11, 1999, Pages 687-698

  Wilson, James M ^a,b   Ferguson III, James J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b NONE   (United States)

Author keywords

Aspirin; Atherosclerosis; Clopidogrel; Endothelium; Glycopro tein IIb IIIa; Platelet; Ticlopidine

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TICLOPIDINE; TIROFIBAN;

ARTERY ENDOTHELIUM; ARTERY THROMBOSIS; ATHEROMA; ATHEROSCLEROSIS; CELL INTERACTION; DRUG INDUCED DISEASE; HUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; REVIEW; RISK BENEFIT ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 0032737735     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960221103     Document Type: Review

References (129)

1. American Heart Association. 1998 Heart and Stroke Statistical Update. Available at: http://www.amhrt.org. Accessed August, 1998
2. Rubanyi GM: The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22(suppl 4):S1-S4
3. Garcia-Palmieri M: The endothelium in health and in cardiovascular disease. PR Health Sci J 1997;16:136-141
4. De Meyer GRY, Herman AG: Vascular endothelial dysfunction. Prog Cardiovasc Dis 1997;39:325-342
5. Wu KK, Thiagarajan P: Role of endothelium in thrombosis and hemostasis. Ann Rev Med 1996;47:315-331
6. Geng JG, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, Bliss GA, Zimmerman GA, McEver RP: Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature 1990;343:757-760
7. Dzau VJ: Pathobiology of atherosclerosis and plaque complications. Am Heart J 1994;128(pt 2):1300-1304
8. Selwyn AP, Kinlay S, Creager M, Libby P, Ganz P: Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. Am J Cardiol 1997;79(5A):17-23
9. Libby P: Atheroma: More than mush. Lancet 1996;348(suppl 1):S4-S7.
10. Fuster V, Gotto AM Jr, Libby P, Loscalzo J, McGill HC Jr: Task Force 1. Pathogenesis of coronary disease: The biologic role of risk factors. J Am Coll Cardiol 1996;27:964-976
11. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801-809
12. Manila KJ, Valtonen VV, Nieminen MS, Asikainen S: Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 1998;26:719-734
13. Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 1998;4:1650-1656
14. Harrison DG: Endothelial dysfunction in atherosclerosis. Basic Res Cardiol 1994;89(suppl 1):87-102
15. Steinberg HO, Bayazeed B, Hook G, Johnson A, Cronin J, Baron AD: Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation 1997;96:3287-3293
16. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135
17. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA: Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993;87:1468-1474
18. Panza JA, Garcia CE, Kilcoyne CM, Quyyumi AA, Cannon RO III: Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995;91:1732-1738
19. Ota Y, Kugiyama K, Sugiyama S, Ohgushi M, Matsumura T, Doi H, Ogata N, Oka H, Yasue H: Impairment of endothelium-dependent relaxation of rabbit aortas by cigarette smoke extract: Role of free radicals and attenuation by captopril. Atherosclerosis 1997;131:195-202
20. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695-1701
21. Blann A, Lip GYH, Islim IF, Beevers DG: Evidence of platelet activation in hypertension. J Hum Hypertens 1997;11:607-609
22. Adams MR, Jessup W, Celermajer DS: Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: Reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol 1997;29:491-497
23. Lin SJ: Risk factors, endothelial cell turnover and lipid transport in atherogenesis. Chung Hua I Hsueh Tsa Chih (Taipei) 1996;58:309-316
24. Calori G, D'Angelo A, Della Valle P, Ruotolo G, Ferini-Strambi L, Giusti C, Errera A, Gallus G: The effect of cigarette-smoking on cardiovascular risk factors: A study of monozygotic twins discordant for smoking. Thromb Haemost 1996;75:14-18
25. Kannel WB, Wolf PA, Castelli W, D'Agostino B: Fibrinogen and risk of cardiovascular disease. The Framingham Study. J Am Med Assoc 1987;258:1183-1186
26. Moghadasian MH, McManus BM, Frolich JJ: Homocyst(e)ine and coronary artery disease. Arch Intern Med 1997;157:2299-2308
27. Rosenson RS, Tangney CC: Antiatherothrombotic properties of statins. Implications for cardiovascular event reduction. J Am Med Assoc 1998;279:1643-1650
28. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI, on behalf of the REGRESS Study Group: Effects of lipid lowering by pravastatin on progression and regression of coronary disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-2540
29. Scandinavian Simvastatin Survival Study Group: Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-1275
30. West of Scotland Coronary Prevention Study Group: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-1445
31. Davies M: Stability and instability: Two faces of coronary atherosclerosis: The Paul Dudley White lecture 1995. Circulation 1996;94:2013-2020
32. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-1375
33. Ross R: Factors influencing atherogenesis. In Hurst's The Heart, Vol 1, 9th ed. (Eds. Alexander RW, Schlant RC, Fuster V), p 1139-1159. New York: McGraw-Hill, 1998
34. Ardissino D, Merlini PA, Ariens R, Coppola R, Bramucci E, Mannucci PM: Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997;349:769-771
35. Ambrose JA, Hjemdahl-Monsen CE, Borneo S, Gorlin R, Fuster V: Angiographic demonstration of a common link between unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 1988;61:244-247
36. Ambrose JA, Weinrauch M: Thrombosis in ischemic heart disease. Arch Intern Med 1996;156:1382-1394
37. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V: Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988;12:56-62
38. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP: Can coronary arteriography predict the site of subsequent myocardial infarction in patients with mild to moderate coronary artery disease? Circulation 1988;78:1157-1166
39. Alderman EL, Corley SD, Fisher LD, Chaitman BR, Faxon DP, Foster ED, Killip T, Sosa JA, Bourassa MG: Five year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993;22:1141-1154
40. Giroud D, Li JM, Urban P, Meier B, Rutishauer W: Relation of the site of myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 1992;69(8):729-732
41. Libby P: Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844-2850
42. Fuster V: Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 1994;90:2126-2146
43. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, Virmani R: Coronary plaque erosion without rupture into a lipid core: A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93:1354-1363
44. Van der Wal A, Becker AE, van der Loos C, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44
45. Folts JD, Crowell EB Jr, Rowe GG: Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976;54:365-370
46. Constantinides P, Chakravarti RN: Rabbit arterial thrombosis production by systemic procedures. Arch Pathol 1961;72:197-202
47. Constantinides P: Experimental Atherosclerosis, p. 25. New York: Elsevier, 1965
48. Abela GS, Picon PD, Friedl SE, Gebara OC, Miyamoto A, Federman M, Tofler GH, Muller JE: Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model. Circulation 1995;91:776-784
49. Kario K, Matsuo T, Kobayashi H, Yamamoto K, Shimada K: Earthquake-induced potentiation of acute risk factors in hypertensive elderly patients: Possible triggering of cardiovascular events after a major earthquake. J Am Coll Cardiol 1997;29(5):926-933
50. Tofler GH, Stone PH, Maclure M, Edelman E, Davis VG, Robertson T, Antman EM, Muller JE: Analysis of possible triggers of acute myocardial infarction (the MILIS study). Am J Cardiol 1990;66(1):22-27
51. Hansen O, Johansson BW, Gullberg B: Circadian distribution of onset of acute myocardial infarction in subgroups from analysis of 10,791 patients treated in a single center. Am J Cardiol 1992;69(12):1003-1008
52. Suzuki S, Sakamoto S, Koide M, Fujita H, Sakuramoto H, Kuroda T, Kintaka T, Matsuo T: Hanshin-Awaji earthquake as a trigger for acute myocardial infarction. Am Heart J 1997;134(5 Pt 1):974-977
53. Leor J, Kloner RA: The Northridge earthquake as a trigger for acute myocardial infarction. Am J Cardiol 1996;77(14):1230-1232
54. Mittleman MA, Maclure M, Sherwood JB, Mulry RP, Tofler GH, Jacobs SC, Friedman R, Benson H, Muller JE: Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators. Circulation 1995;92(7):1720-1725
55. Willich SN, Lewis M, Lowel H, Amtz HR, Schubert F, Schroder R: Physical exertion as a trigger of acute myocardial infarction. Triggers and Mechanisms of Myocardial Infarction Study Group. N Engl J Med 1993;329(23):1684-1690
56. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE: Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med 1993;329(23):1677-1683
57. Winther K, Hillegass W, Tofler GH, Jimenez A, Brezinski DA, Schafer AI, Loscalzo J, Williams GH, Muller JE: Effects on platelet aggregation and fibrinolytic activity during upright posture and exercise in healthy men. Am J Cardiol 1992;70(11):1051-1055
58. Bainton D, Jones GR, Hole D: Influenza and ischaemic heart disease - a possible trigger for acute myocardial infarction? Int J Epidemiol 1978;7(3):231-239
59. Wang JS, Jen CJ, Chen HI: Effects of chronic exercise and deconditioning on platelet function in women. J Appl Physiol 1997;83(6):2080-2085
60. Wallen NH, Held C, Rehnqvist N, Hjemdahl P: Effects of mental and physical stress on platelet function in patients with stable angina pectoris and healthy controls. Eur Heart J 1997;18(5):807-815
61. Rock G, Tittley P, Pipe A: Coagulation factor changes following endurance exercise. Clin J Sport Med 1997;7(2):94-99
62. Harker LA: Pathogenesis of thrombosis. In Hematology, 4th ed. (Eds. Williams WJ, Beutler E, Erslev AJ, Lichtman MA), p. 1559-1569. New York: McGraw-Hill, 1990
63. Ruoslahti E: Integrins. J Clin Invest 1991;87:1-5
64. Schafer AI: Antiplatelet therapy with glycoprotein IIb/IIIa receptor inhibitors and other novel agents. Tex Heart Inst J 1997;24:90-96
65. Fuster V, Verstraete M: Hemostasis, thrombosis, fibrinolysis, and cardiovascular disease. In Heart Disease: A Textbook of Cardiovascular Medicine, Vol 2, 5th ed. (Ed. Braunwald E), p. 1809-1842. Philadelphia: W.B. Saunders Co., 1997
66. Kieffer N, Phillips DR: Platelet membrane glycoproteins: Functions in cellular interactions. Am Rev Cell Biol 1990:6:329-357
67. Turitto VT, Baumgartner HR: Platelet-surface interactions. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 2nd ed., (Eds. Colman RW, Hirsh J, Marder VJ, Salzman EW), p. 555-571. Philadelphia: JB Lippincott Co., 1987
68. Schror K: Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Sem Thromb Hemost 1997;23:349-356
69. Ruggeri ZM: Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997;78:611-616
70. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106
71. Schafer AI: Antiplatelet therapy. Am J Med 1996;101:199-209
72. Dabaghi SF, Kamat SG, Payne J, Marks GF, Roberts R, Schafer AI, Kleiman NS: Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects. Am J Cardiol 1994;74:720-723
73. FitzGerald GA, Brash AR, Oates JA, Pedersen AK: Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest 1983;71:1336-1343
74. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-2336
75. Helgason CM, Tortorice KL, Winkler SR, Penney DW, Schuler JJ, McClelland TJ, Brace LD: Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-350
76. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD: Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988;71:1366-1374
77. Rajagopalan S, McIntire LV, Hall ER, Wu KK: The stimulation of arachidonic acid metabolism in human platelets by hydrodynamic stresses. Biochem Biophys Acta 1988;958:108-115
78. Buchanan MR, Blister SJ: Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 1995;11:221-227
79. Guslandi M: Gastric toxicity of antiplatelet therapy with low-dose aspirin. Drugs 1997;53:1-5
80. Alimento M, Campodonico J, Santambrogio G, Rossi M, Trabattoni D, Celeste F, Guazzi M: Aspirin antagonism as a reflection of prostaglandin participation in the antihypertensive properties of ACE-inhibitors. Cardiologia 1997;42:605-610
81. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstan MA: Antiplatelet agents and survival: A cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial. J Am Coll Cardiol 1998;31:419-425
82. Hall D, Zeitler H, Rudolph W: Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-1555
83. Nguyen KN, Aursnes I, Kjekshus J: Interaction between enalapril and aspirin on mortality after acute myocardial infarction: Subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997;79:115-119
84. Polonia J: Interaction of antihypertensive drugs with anti-inflammatory drugs. Cardiology 1997;88(suppl 3):47-51
85. Venturini CM, Isakson P, Needleman P: Non-steroidal anti-inflammatory drug-induced renal failure: A brief review of the role of cyclo-oxygenase isoforms. Curr Opin Nephrol Hypertens 1998;7:79-82
86. ESPS Group: European Stroke Prevention Study. Stroke 1990;21:1122-1130
87. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2. Dipyridamoleand acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13
88. Hess H, Mietaschik A, Deichsel G: Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: A prospective double-blind arteriographically controlled trial. Lancet 1985;1:415-419
89. FitzGerald GA: Dipyridamole. N Engl J Med 1987;316:1247-1257
90. Keltz TN, Innerfield M, Gitler B, Cooper JA: Dipyridamole-induced myocardial ischemia. J Am Med Assoc 1987;257:1515-1516
91. Hass WK, Easton JD: Changing concepts of the pathophysiology of cerebral myocardial infarction. In Ticlopidine, Platelets and Vascular Disease (Eds. Hass WK, Easton JD), p. 1-12. New York: Springer-Verlag, 1993
92. Saltiel E, Ward A: Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987;34:222-262
93. Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M: Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985;75:328-338
94. Cattaneo M, Lombardi R, Bettega D, Lecchi A, Mannucci PM: Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler Thromb 1993;13:393-397
95. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B: Ticlopidine Aspirin Stroke Study Group. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507
96. Bellavance A, for the Ticlopidine Aspirin Stroke Study Group: Efficacy of ticlopidine and aspirin for prevention of reversible cerebrovascular ischemic events. Stroke 1993;24:1452-1457
97. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-1220
98. Limet R, David J-L, Magotteaux P, Larock M-P, Rigo P: Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: A double-blind study. J Thorac Cardiovasc Surg 1987;94:773-783
99. The TIMAD Study Group: Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990;108:1577-1583
100. Bergqvist D, Almgren B, Dickinson J: Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: Results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg 1995;10:69-76
101. Blanchard J, Carreras LO, Kindermans M, and the EMATAP Group. Results of EMATAP: A double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Now Rev Fr Hematol 1993;35:523-528
102. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089
103. Schühlen H, Hadamitzky M, Walter H, Ulm K, Schömig A: Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: Analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation 1997;95:2015-2021
104. Schömig A, Neumann FJ, Walter H, Schuhlen H, Hadamitzky M, Zitzmann-Roth EM, Dirschinger J, Hausleiter J, Blasini R, Schmitt C, Alt E, Kastrati A: Coronary stent placement in patients with acute myocardial infarction: Comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997;29:28-34
105. Berger PB, Bell MR, Grill DE, Melby S, Holmes DR Jr: Frequency of adverse clinical events in the 12 months following successful intracoronary stent placement in patients treated with aspirin and ticlopidine (without warfarin). Am J Cardiol 1998;81:713-718
106. Goods CM, al-Shaibi KF, Liu MW, Yadav JS, Mathur A, Jain SP, Dean LS, Iyer SS, Parks JM, Roubin GS: Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol 1996;78:1042-1044
107. Neumann FJ, Gawaz M, Dickfeld T, Wehinger A, Walter H, Blasini R, Schömig A: Antiplatelet effect of ticlopidine after coronary stenting. JAm Coll Cardiol 1997;29:1515-519
108. Rupprecht HJ, Darius H, Borkowski U, Voigtlander T, Nowak B, Genth S, Meyer J: Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation 1998;97:1046-1052
109. Ticlid® (ticlopidine hydrochloride). Physicians' Desk Reference, 51st ed., p. 2317-2319. Montvale, NJ: Medical Economics Company, 1997
110. Coukell AJ, Markham A: Clopidogrel. Drugs 1997;54:745-750
111. Herbert JM, Tissinier A, Defreyn G, Maffrand JP: Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 1993;13:1171-1179
112. Herbert JM, Bernat A, Maffrand JP: Importance of platelets in experimental venous thrombosis in the rat. Blood 1992;80:2281-2286
113. Roald HE, Barstad RM, Kierulf P, Skjorten F, Dickinson JP, Kieffer G, Sakariassen KS: Clopidogrel - a platelet inhibitor which inhibits thrombogenesis in non-anticoagulated human blood independently of the blood flow condition. Thromb Haemost 1994;71:655-662
114. Bachmann F, Savcic M, Hauert J, Gaudelin B, Kieffer G, Cariou R: Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel (abstr), p. 1483. Eur Heart J 1996;17(suppl):263
115. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339
116. Gent M: Benefit of clopidogrel in patients with coronary disease (abstr). Circulation 1997;96:I-467
117. Plavix® (clopidogrel bisulfate tablets). Full Prescribing Information. New York: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, 1997
118. Faulds D, Sorkin EM: Abciximab(c7E3 Fab): A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs 1994;48:583-598
119. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961
120. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696
121. The CAPTURE Investigators: Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435
122. The EPISTENT Investigators: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352(9122):87-92
123. IMPACT-II Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-1428
124. PRISM Study Investigators: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505
125. PRISM-PLUS Study Investigators: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497
126. Théroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ: Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation 1996;94:899-905
127. Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E: Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1998;97:340-349
128. Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ: Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation 1997;96:1117-1121
129. Vorchheimer DA, Fuster V: Oral platelet glycoprotein IIb/IIIa receptor antagonists: The present challenge is safety (editorial). Circulation 1998;97:312-314